Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN, July 14 (Reuters) ...

German chemicals giant Bayer said on Thursday it was selling its male testosterone replacement drug Nebido for up to half-a-billion euros in order to concentrate on medical innovation. The Barron's ...

Indevus Pharmaceuticals Inc. gained U.S. rights to Nebido, an injectable treatment for hypogonadism developed and previously launched in Europe by Berlin-based Schering AG. Terms call for Indevus to ...

Shares of Indevus Pharmaceuticals Inc. plunged nearly 70 percent after the company reported at least a two-year setback for Nebido, its three-month formulation of testosterone, for male hypogonadism ...

BANGALORE, June 4 (Reuters) - Indevus Pharmaceuticals Inc's injectable testosterone drug's approval may be delayed by two years, as U.S. health regulators are expected to ask for more safety data, ...

BERLIN, July 14 (Reuters) - Bayer (BAYGn.DE), opens new tab is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 ...